The researcher of the Bellvitge Biomedical Research Institute (IDIBELL) and the Bioinformatics Unit for Precision Oncology (UBOP) of the ICO L’Hospitalet, Sara Hijazo, presented and won the award for the “best oral communication” at the XIV Congress of Lung Cancer that was held from November 10 to 12 and organized by the Spanish Group of Lung Cancer.

Under the title, “Re-definition of lung adenocarcinoma transcriptional subtypes using integrative bioinformatic approaches”, David Cordero, Ania Alay, Raúl Marín, Xavier Solé, and Ernest Nadal have collaborated in the work.

What does this study explain?

The work presented at the congress explains how, through the bioinformatic analysis of more than 4,500 gene expression profiles of lung adenocarcinomas, this study has identified seven molecular subtypes that show differences in the behavior of 50 molecular signaling pathways essential for the proper functioning of the cells. These groups show differences in the level of overall survival and molecular characteristics.

Additionally, specific potential treatments for each group have been identified using massive pharmacogenomic data. “The results of this study may pave the way to obtain a more precise classification of lung adenocarcinomas, as well as to define new therapeutic strategies beyond current targeted therapies based on specific genomic alterations” concludes Sara Hijazo, a researcher at IDIBELL, ICO, and UBOP.

The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.

IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).